Innovotech Inc. (TSX Venture Exchange: IOT; OTCQB: IOTCF), a life sciences services and technology company, reported financial results for the three months ended March 31, 2026, revealing a 44% decline in revenue to $648,140 compared to the same period in the prior year. The decrease was driven almost entirely by a change in activities for a large project with a major customer, which had been expected to continue through 2026.
Gross profit for the quarter was $202,231, with a gross margin of 31.2%, down from 53.6% in Q1 2025. Margins were negatively impacted by underutilized capacity as the company maintained staffing and operational readiness in anticipation of executing the planned customer work. The company recorded a net loss of $401,295 for the quarter, compared to net income of $63,523 in Q1 2025. Operating expenses increased year over year, reflecting the integration of Keystone Labs and Innovotech Labs, relocation of the former Keystone Labs operations to a new facility, and investments in a stronger sales organization.
Despite the quarterly loss, Innovotech continues to advance its strategic transformation, including strengthening its leadership and commercial teams, and completing its OTCQB listing in the United States. The company operates with a strong liquidity position and maintains a meaningful equity base, providing flexibility to manage near-term volatility while executing its longer-term strategy.
“Management remains committed to investing in a more diversified, resilient, and scalable platform,” said Innovotech CEO Craig Milne. “The Company is continuing to execute its transformation strategy with a focus on the operational and commercial initiatives required to support long-term growth and reduce revenue concentration risk.”
The company’s unaudited consolidated financial statements and Management’s Discussion and Analysis have been filed on SEDAR+ and the OTCIQ. Innovotech is a recognized leader in biofilm science and antimicrobial testing, operating through ISO-certified and GMP-accredited laboratories. The company provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development, and its MBEC Assay® platform is widely used for high-throughput antimicrobial and antibiotic testing. More information is available at https://www.innovotech.ca.
The financial results highlight the challenges of client concentration, but management's focus on diversification and investment in new capabilities positions the company to mitigate such risks in the future. The strategic initiatives, including the OTCQB listing and expansion of service offerings, are aimed at generating consistent recurring revenue and reducing dependence on any single customer.
